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THE reduction of Ring A of adrenal steroids by the A4-steroid hydrogenases of
liver has been shown in man (Peterson, Wyngaarden, Guerra, Brodie and Bunim,
1958) and in the rat (Glenister and Yates, 1961) to be the rate-controlling step
in the inactivation of corticosteroids. Urquhart, Yates and Herbst (1959) have
further shown that there is a close correlation between adrenal size and the level
of this enzyme system in the liver. Thus under experimental conditions where a
rise in the activity of this enzyme was induced, for example by treatment with
thyroxine (Yates, Urquhart and Herbst, 1958) or castration of male rats (Yates,
Herbst and Urquhart, 1958), there was an increase in adrenal weight; conditions
which produced a reduction in enzymic activity, such as partial hepatectomy
(Urquhart et al., 1959), caused adrenal atrophy. Administration of corticotro-
phin or cortical hormones, on the other hand, did not increase the inactivating
capacity of the liver (Urquhart et al., 1959). These authors therefore concluded
that it is the level of hepatic A4-steroid hydrogenase activity which determines
adrenal size rather than the reverse.
Since adrenal hypertrophy is a common feature of tumour-bearing animals
(Begg, 1958) the present study was undertaken to determine whether the
presence of a growing tumour affected the rate of hepatic reduction of Ring A of
adrenal steroids.
EXPERIMENTAL METHODS
Animals
Virgin female albino rats were fasted overnight and those weighing 140-160 g.
were selected and housed in individual cages.
Treatment of animals
The animals were anaesthetised with ether and the experimental group
injected intramuscularly into the right thigh with 1 ml. portions of a suspension
of Walker 256 carcinoma, prepared as described by Talalay, Takano and Huggins
(1952). The control group received an intramuscular injection of 1 mrnl. 0.9
per cent saline.
Throughout the experimental period both groups of rats were fed a diet ade-
quate in calories and protein content as described previously (Clark and Goodlad,
1960).
The rats were killed at various time intervals after injection by stunning and
exsanguination. The liver, adrenal glands and tumour were rapidly removed
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Determination of hepatic A4-steroid hydrogenase activity
Liver slices, prepared using the tissue slicer described by McIlwain and Buddle
(1953), were assayed for A4-steroid hydrogenase activity essentially as described
by Urquhart et al. (1959) save that the amount of slice assayed was 50 mg. and
the amount of corticosterone added to each assay was 0.55 jtmoles. Under
these conditions it was found that the rate of reduction of corticosterone was
proportional to the time ofincubation during the first 30 minutes and the enzyme
activity proportional to the weight of slice between 50-100 mg.
The reaction was stopped by the addition of 20 ml. redistilled methylene
chloride and the steroid quantitatively extracted by shaking. The amount of
corticosterone reduced was measured as described by Tomkins (1957).
RESULTS
The assay of hepatic A4-steroid hydrogenase activity was carried out using
corticosterone as substrate since this is the principle steroid secreted by the rat
adrenal (Bush, 1953).
The size ofthe Walker 256 carcinoma at the various times ofkilling are shown
in Table I. At 30 hours it was impossible to distinguish any tumour tissue.
TABLE I.-Tumour Weight at Various Time Intervals After Tumour Inoculation
Results are the means of 6 experiments ± S.E.
Time after injection
30 hours 3 days 5 days 7 days
Tumourweight (g.) . - 01±0 08 2-9±0 5 9 7+±0- 9
This was also the case on the third day save for two of the six animals which had
tumours of 0.2 g. and 0.4 g. respectively. By the fifth day the growth of the
tumour was well established.
TABLE II.-The Effect of the Walker 256 Carcinoma on theConcentration ofHepatic
A4-Steroid Hydrogenase Activity
Results are expressed as the means i S.E. Figures in parentheses refer
to the number of animals in each group
umoles corticosterone reduced/15 min./g. liver slice
Time after injection
30 hours 3 days 5 days 7 days
Control group . . . 2-28±030 2-05±0-15 1.87+0 27 1 81±0-09
(4) (5) (6) (6)
Tumour-bearing group . 2.54+0-15 2.30+0-12 2.40+0-18 1*96-0.19
(4) (6) (6) (6)
P* . . . . . >0.40 >0. 20 >0.10 >0*40
*Statistical analysis in this and subsequent tables carried out by Student's "t" test.
Table II shows the concentration of hepatic A4-steroid hydrogenase activity
(,tmoles corticosterone reduced/15 min./g. liver slice) at several time intervals
after injection. There was no significant difference between the control and
834STEROID INACTIVATION AND TUMOUR GROWTH
tumour-bearing groups at any of the time intervals studied. There was also no
significant variation within either group with time.
The effect of tumour growth on the total hepatic A4-steroid hydrogenase
activity (,moles corticosterone reduced/15 min./liver/100 g. initial body weight)
is shown in Table III. There was a significant increase in the total activity as
TABLE III.-The Effect of the Walker 256 Carcinoma on the Total Hepatic
A4-Steroid Hydrogenase Activity
Results are expressed as the means i S.E. Figures in parentheses refer
to the number of animals in each group
pmoles corticosterone reduced/S15 min./liver/100 g. initial body weight
Time after injection
-A
30 hours 3 days 5 days 7 days
Control group . . . 701 ± 110 5 96±0 50 5 86±0- 96 5 44±023
(4) (5) (6) (6)
Tumour-bearing group . 10-30±i0-67 8-43±0-68 10-22±1-37 9-04±1-34
(4) (6) (6) (6)
P . . . . . <005 <0-02 <0.05 <0-05
early as 30 hours after injection of tumour and this increase was maintained
throughout the period of tumour growth studied. This early rise in enzyme
activity was associated with enlargement ofthe livers ofthese animals (Table IV).
TABLE IV.-The Effect of the Walker 256 Carcinoma on Liver Weight
Results are expressed as the means ± S.E. Figures in parentheses refer
to the number of animals in each group
g. liver/100 g. initial body weight
Time after injection
r
30 hours 3 days 5 days 7 days
Control group . . 3 04+±0-11 2 90+±0 17 3-09±0 07 3-02+±0-10
(4) (5) (6) (6)
Tuinour-bearing group . 4 06±- 08 3 64±0 + 13 4-22±0 i
-29 4- 50±0*28
(4) (6) (6) (6)
P . . . . <0-01 <0-01 <0-01 <0.01
The results in Table V indicate that this increased activity of the A4-steroid
hydrogenase was accompanied by adrenal hypertrophy. The adrenals showed a
significant increase in weight at 30 hours and this was maintained throughout
the 7-day period.
DISCUSSION
The total A4-steroid hydrogeiiase activity is increased in the livers of rats
bearing the Walker 256 carcinoma. This increase is observed as early as 30 hours
after tumour inoculation and is accompanied by an increase in adrenal size.
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TABLE V.-The Effect of the Walker 256 Carcinoma on Adrenal Weight
Results are expressed as the means ± S.E. Figures in parentheses refer
to the number of animals in each group
mg. adrenal/100 g. initial body weight
Time after injection
r~~
30 hours 3 days 5 days 7 days
Control group . . 29-1 30-1 31±i2 331
(4) (5) (6) (6)
Tumour-bearing group . 40±i3 39±i2 42±1 45±4
(4) (6) (6) (6)
P . . . . . <0 05 <0.01 <0.01 <0-02
Ball and Samuels (1938) failed to observe adrenal hypertrophy in hypo-
physectomised rats bearing the Walker 256 carcinoma, a finding which indicates
that the increase in adrenal size is due to an increased production of cortico-
trophin (Begg, 1958).
The level of circulating corticosteroids influences the control of the secretion
of corticotrophin by a negative feedback mechanism (Sayers and Sayers, 1947)
and Urquhart et al. (1959) have demonstrated that hepatic inactivation ofadrenal
corticoids by Ring A reduction can be a principal determinant in this control.
Our experimental conditions do not exclude the possibility that the adrenal
hypertrophy may occur through a direct action on the hypothalamus-pituitary
system and that the observed increase in hepatic A4-steroid hydrogenase activity
is merely an adaptation to an increased availability of substrate. However it
must be pointed out that direct attempts to simulate wide variations in adrenal-
cortical function did not cause parallel changes in the capacity of the liver to
inactivate corticosteroids (Urquhart et al., 1959). We would suggest therefore
that the marked increase in hepatic A4-steroid hydrogenase activity observed
during the growth of the Walker 256 carcinoma is due to a direct action on this
enzyme system and that this effect plays a significant role in the production of
adrenal hypertrophy in the tumour-bearing rat.
The mechanism whereby the A4-steroid hydrogenase activity is raised cannot
be ascertained from the present work. However the fact that we have observed
these effects so soon after implantation of the tumour suggests that the initial
changes in hepatic enzyme activity might be caused by some factor present in
the tumour inoculum.
SUMMARY
1. The effect of the Walker 256 carcinoma on hepatic A4-steroid hydrogenase
activity was studied in rats during the first 7 days of tumour growth.
2. The total hepatic A4-steroid hydrogenase activity was increased markedly
as early as 30 hours after implantation of the tumour and elevated levels were
observed throughout the period studied.
3. This increase in hepatic enzyme activity was accompanied by an increase
in adrenal weight.
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836STEROID INACTIVATION AND TUMOUR GROWTH 837
cinoma. This investigation was supported by a grant from the Medical Research
Council which is gratefully acknowledged.
REFERENCES
BALL, H. A. AND SAMUELS, L. T.-(1938) Proc. Soc. exp. Biol., N.Y., 38, 441.
BEGOG, R. W.-(1958) Advanc. Cancer Res., 5, 1.
BUSH, I. E.-(1953) J. Endocrin., 9, 95.
CLARK, C. M. AND GOODLAD, G. A. J.-(1960) Brit. J. Cancer, 14, 327.
GLENISTER, D. W. AND YATES, F. E.-(1961) Endocrinology, 68, 747.
MCILWAIN, H. AND BUDDLE, H. L.-(1953) Biochem. J., 53, 412.
PETERSON, R. E., WYNGAARDEN, J. B., GuERRA, S. L., BRODIE, B. B. AND BUNIM, J. J.-
(1958) J. clin. Invest., 34, 1779.
SAYERS, G. AND SAYERS, M. A.-(1947) Endocrinology, 40, 265.
TALALAY, P., TAKANO, G. M. V. AND HUGGINS, C.-(1952) Cancer Res., 12, 834.
TOMKINS, G. M.-(1957) J. biol. Chem., 225, 13.
URQUHART, J., YATES, F. E. AND HERBST, A. L.-(1959) Endocrinology, 64, 816.
YATES, F. E., HERBST, A. L. AND URQUHART, J.-(1958) Ibid., 63, 887.
YATES, F. E., URQUHART, J. AND HERBST, A. L.-(1958) Amer. J. Physiol.. 195, 373.